Table: Taisho Pharmaceutical HD -2022/23 parent results
May 11 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2023 Mar 31, 2022 Mar 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 8.21 10.03
(-18.2 pct) (+138.9 pct)
Operating 6.63 8.36
(-20.7 pct) (+235.7 pct)
Recurring 6.56 8.26
(-20.6 pct) (+235.0 pct)
Net 6.01 10.69
(-43.8 pct) (+472.1 pct)
EPS 73.26 yen 131.16 yen
EPS Diluted 73.17 yen 131.01 yen
Ann Div 100.00 yen 100.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10